Engflag

Mold

Quick links to important sections

Mold

Mold_PL

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mold

This section defines the medicine known commercially as Mold, detailing its composition, pharmacological classification, and general purpose, strictly avoiding details on dosage, administration, side effects, or warnings.

Property Description
Active ingredient Racecadotril
Form Capsules, Tablets, Granules for Oral Suspension
Pharmacological class Antisecretory Antidiarrheal / Enkephalinase Inhibitor
Common use Relief of acute fluid-losing diarrhea
Origin Synthetic compound (Prodrug)

What is Mold and Its Pharmacological Identity?

Mold is a synthetic single-ingredient pharmaceutical agent used as an antisecretory antidiarrheal drug. Its active substance is the compound Racecadotril, which places it in the specific pharmacological class of Enkephalinase Inhibitors. This classification defines the drug by its targeted action on a specific intestinal enzyme. The compound is a prodrug, meaning it requires metabolism within the body after oral administration to become pharmacologically active. Racecadotril acts to modulate intestinal secretion, which distinguishes its function from other drug classes. This mechanism assists the body in retaining necessary fluids.

Composition, Forms, and General Therapeutic Purpose

The medicine's primary component is the synthetic compound Racecadotril, which is supplied in forms suitable for various patient groups, including pediatric populations. It is available as capsules and tablets for use in adults, and as flavorless granules for oral suspension for children. The general therapeutic purpose of Mold is to help reduce the volume and frequency of watery stools. Its function is to facilitate the normalization of intestinal fluid balance in scenarios involving acute, non-complicated secretory diarrhea. This antisecretory mechanism limits the excessive secretion of water and electrolytes without affecting intestinal motility.

What side effects are possible with Mold?

Possible Side Effects and Safety Information

The official safety profile for the active ingredient, Racecadotril (Mold), details adverse reactions and specific usage constraints as classified in regulatory documents. These effects are formally categorized by frequency and the body system affected.

Documented Adverse Reactions

The most frequently reported undesirable effect classified as Common is headache. Uncommon adverse reactions include rash, erythema (skin redness), and tonsillitis, which is primarily noted in the pediatric population.

Serious Reactions and Unknown Frequencies

Regulatory safety information highlights the potential for rare but serious reactions, often reported during post-marketing surveillance and classified as Frequency Not Known. These include severe hypersensitivity reactions such as Angioedema, which involves swelling of the face, tongue, lips, or eyelids and may lead to life-threatening airway obstruction. Additionally, Severe Cutaneous Adverse Reactions (SCARs), including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Anaphylactic shock, are documented.

Safety Constraints and Special Populations

Use is subject to specific regulatory limitations. The medicine is generally not recommended or contraindicated in individuals with severe hepatic (liver) or renal (kidney) impairment due to insufficient safety data in these groups. It is also advised to avoid use during pregnancy and breastfeeding. The product is contraindicated in cases of diarrhoea associated with blood, pus, or high fever, as this may signal an invasive disease. Concomitant use with ACE Inhibitors may also increase the risk of angioedema.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the official information regarding Mold (Racecadotril) overdose and regulator-mandated emergency actions, strictly as presented in government regulatory documentation.

Overdose Scope

Domain Description (Strictly from Regulatory Sources)
Documented Overdose Presentations Regulatory reports document sporadic cases of overdose that occurred without adverse events being reported.
Physiological Systems Affected No specific physiological systems are listed as affected by overdose; however, severe reactions such as angioedema carry a risk of airway obstruction and require immediate action.
Dose-related Factors Single doses above 2 grams (equivalent to 20 times the therapeutic dose) were administered to adults without harmful effects described.
Population-specific Overdose Notes The documented tolerance of doses 20 times the therapeutic level is specifically reported for adults.
Emergency-response Statements Management of overdose should follow recognised procedures for overdose. For severe reactions, the treatment has to be stopped immediately.
When immediate medical help is required Close medical supervision and appropriate monitoring are required for severe reactions (e.g., angioedema) until symptoms have completely and definitively disappeared.

Overdose Classifications (High-Level)

Classification Description (as defined in official documents)
Severity Classification No harmful effects described even at doses 20 times the therapeutic dose. Severe outcomes are associated with life-threatening adverse reactions (SARs) that mandate urgent care.
Antidote Availability No specific antidote has been identified.

Resulting Overdose Structure

Official overdose statements:

  • Manifestation: Sporadic cases of overdose have been reported without associated adverse events.
  • Toxicity: Adults tolerated doses up to 20 times the therapeutic dose with no described harmful effects.
  • Antidote: No specific antidote is known.
  • Mandated Action: For severe cutaneous adverse reactions (SCARs) or angioedema, the treatment must be stopped immediately, and close medical supervision is required.

Connection to the overall overdose profile

The regulatory overdose profile for Mold is defined by the documented absence of toxicity, even at significantly high doses in adults. Despite the low inherent toxicity, official labeling mandates immediate medical attention and discontinuation if severe, potentially life-threatening reactions such as angioedema or DRESS occur. Because no specific antidote has been identified, any required care focuses on general supportive and symptomatic management, following established clinical procedures.

Therapeutic Uses of Mold

The medication is applied in clinical settings that involve acute or unstable symptom patterns, and is used for managing acute diarrhea. Its application is for the complementary symptomatic treatment of acute diarrhea in infants, children, and adults, often used alongside Oral Rehydration Therapy (ORT).

Easing Acute Watery Stool Frequency and Volume

Mold is used for managing symptoms related to heightened physiological activity, such as high frequency and large volume of watery stools. It is commonly used across conditions presenting with acute episodes. This support is associated with managing the overall symptom volume and is used in maintaining physiological balance when symptoms are more noticeable.

Supporting Fluid Management and Comfort

The medication is relevant in conditions characterized by periods of heightened symptoms and is commonly used with supportive measures to manage fluid balance. By assisting with the management of continuous fluid loss, it supports patients during clinical episodes by addressing fluid-related distress and contributes to improved patient comfort.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

  1. Scottish Medicines Consortium's guidance on racecadotril

Eligibility and Restrictions for Use

The eligibility for Mold (Racecadotril) is defined by official regulatory bodies, classifying patients into approved, restricted, and prohibited groups based on age, physiological status, and co-existing conditions.

Eligibility Status Applicable Populations
Approved Use Adults, adolescents, and children over 3 months of age are the approved age groups for the symptomatic treatment of acute diarrhea. Use in older adults is generally permitted.
Contraindicated Use is strictly prohibited for patients with known hypersensitivity to the active substance or excipients. Absolute contraindications include specific rare hereditary disorders such as fructose intolerance or glucose-galactose malabsorption.
Use Not Recommended The medicine is not recommended for infants under 3 months of age as safety has not been established. Furthermore, it is not recommended for administration during pregnancy or breastfeeding due to a lack of sufficient supporting clinical data.

Eligibility is further restricted for patients with severe hepatic impairment or severe renal impairment, for whom use is not recommended due to limited data in these populations. The medicine is also not administered in cases of diarrhea with invasive features (fever, bloody or purulent stools) or chronic diarrhea, as defined by regulatory context constraints.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for Mold (Racecadotril) as stated in regulatory prescribing information.

Documented Pharmacodynamic and Pharmacokinetic Interactions

Interaction Type Interacting Substance/Class Official Regulatory Statement
High-Risk Pharmacodynamic ACE Inhibitors (e.g., Captopril, Enalapril) Increased risk of angioedema (additive effect). Co-administration is restricted for patients with a relevant history.
Pharmacokinetic Profile CYP/UGT Enzymes Documented low potential for interference; the drug does not induce or inhibit major enzyme systems to a clinically relevant degree.
Food Interaction Food/Meals Delays the time to peak concentration (Cmax) by 60 to 90 minutes; the overall amount absorbed (AUC) remains unchanged.
Documented Non-Interaction Loperamide or Nifuroxazide Official studies confirm no modification of Racecadotril kinetics upon co-administration.

Regulatory Summary of Constraints

The primary constraint noted in official documents is the restricted use with ACE Inhibitors due to the risk of angioedema potentiation. Regulatory data confirm that the drug’s metabolic profile via major CYP/UGT enzymes presents a low potential for pharmacokinetic interaction with other medicines. Cautions are noted for use in patients with hepatic or renal impairment due to limited interaction data in these specific populations. The administration timing is preferably before main meals due to the documented effect on the rate of absorption.

Mechanism of Action

The mechanism of toxicity for certain mold-derived metabolites, such as Aflatoxin B1 (AFB1), begins with selective accumulation in hepatic tissue. The parent compound undergoes biotransformation by liver microsomal Cytochrome P450 enzymes (CYP1A2 and CYP3A4), converting it into the highly reactive intermediate, AFB1-8,9-epoxide (AFBO). This reactive metabolite functions as an electrophilic alkylating agent. The primary biological target is the cellular DNA, forming covalent adducts with the N7 position of guanine residues. This molecular interaction interrupts the fidelity of the genome. The resulting DNA damage triggers mispairing during replication, leading to characteristic G o T transversion mutations. These intracellular events disrupt normal cell cycle regulation and suppress intrinsic DNA damage repair pathways. The downstream cascade involves the dysregulation of key cell cycle proteins. At the system level, this sustained genotoxicity and resulting genomic instability culminate in extensive cellular apoptosis and uncontrolled cellular proliferation in the affected organs.

Dosage and Administration Information

How to Use Mold (Racecadotril)

The administration of Mold follows established protocols detailing its short-term use as a complementary oral treatment. This medication is taken exclusively via the oral route across all approved formulations. It is explicitly indicated for use only as an adjunct to necessary Oral Rehydration Therapy (ORT).

Standard Dosing and Frequency

Population Initial Dose Maintenance Dose and Frequency
Adults 100 mg (one capsule) 100 mg three times daily (t.i.d.)
Pediatrics Weight-based (approx. 1.5 mg/kg) 1.5 mg/kg per dose, three times daily (t.i.d.)

Administration Requirements and Duration

The treatment course is defined by a clear endpoint and a maximum time limit. Administration is continued until two normal stools are recorded, after which treatment ceases. The total duration of use does not exceed 7 days. Long-term or maintenance use of this medicine is not recommended.

For adults, capsules are preferably taken before the main meals. The pediatric formulation, consisting of granules, is mixed with a small amount of food, water, or infant formula and administered immediately after preparation. If a dose is missed, standard practice is to not take a double dose; the next dose is taken at the usual time.

Specialized instructions govern use in certain groups. While no dosage adjustment is necessary for older adults, the medicine is not to be administered to infants less than 3 months old.

Recent Clinical Evidence

Recent Clinical Evidence

Clinical and epidemiological research on mold exposure primarily focuses on respiratory and allergic outcomes associated with indoor dampness. Studies consistently show an association between living or working in damp buildings with mold and the development or exacerbation of asthma, allergic rhinitis (hay fever), cough, and wheeze in both allergic and non-allergic individuals. Allergic reactions to inhaled mold spores are common and may be immediate or delayed.

Types of Associated Conditions

Research has established sufficient evidence of an association between indoor dampness/mold and specific health conditions, including:

  • Respiratory: Asthma, bronchitis, upper respiratory tract symptoms, and respiratory infections.
  • Allergic/Immune: Allergic rhinitis, eczema, and hypersensitivity pneumonitis (a rare, non-infectious inflammatory lung condition).

Severe health effects, such as deep-seated fungal infections like aspergillosis, primarily affect individuals who are severely immunocompromised or those with chronic lung diseases.

Mycotoxin and Systemic Effects

Certain molds produce mycotoxins, which are substances that can be toxic if ingested. Current scientific evidence regarding whether inhaled mycotoxins in typical residential or office environments cause systemic illnesses, such as chronic fatigue, memory loss, or neurological disorders, is complex. While some studies suggest a potential link, the general scientific consensus indicates that the causal association remains weak or unproven in the general population, although research in this area is ongoing. Clinicians interpret environmental exposure history alongside clinical symptoms, as individual susceptibility varies widely.

How should Mold be stored and disposed of?

How to Store and Dispose of Mold (Racecadotril)

The storage and disposal instructions for Mold (Racecadotril) are defined by official regulatory labeling to ensure product integrity and safety.

Storage Requirements

  • No special storage conditions are required for the final packaged product, such as the granules in sachets.
  • The medicine must be kept out of the sight and reach of children.
  • Once the granules for oral suspension are dispersed in water or food, they must be administered immediately; storage after reconstitution is prohibited.

Disposal Instructions

  • Unused or expired product must not be thrown away via wastewater or household waste.
  • Consult a pharmacist on how to properly discard the medicine to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGeorgia

Equivalent of Mold found in:

A-Z Index: